Literature DB >> 30472772

Hepatitis C: Is eradication possible?

Andrea Lombardi1,2, Mario U Mondelli1,2.   

Abstract

Hepatitis C has a relevant global impact in terms of morbidity, mortality and economic costs, with more than 70 million people infected worldwide. In the resolution, "Transforming our world: the 2030 Agenda for Sustainable Development" was included as a focus area in the health-related goal with world leaders pledging to "combat" it by 2030. In response, WHO drafted the Global Viral Hepatitis Strategy carrying the ambitious targets to reduce the number of deaths by two-thirds and to increase treatment rates up to 80%. Despite the availability of highly effective therapeutic regimens based on direct-acting antivirals many barriers to HCV eradication still remain. They are related to awareness of the infection, linkage to care, availability of the therapeutic drug regimens and reinfection. Overall, if an effective prophylactic vaccine will not be available, HCV eradication appears difficult to achieve in the future.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  DAA; HCV; HCV-vaccine; linkage to care; viral eradication

Mesh:

Substances:

Year:  2019        PMID: 30472772     DOI: 10.1111/liv.14011

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  24 in total

1.  Cost-effectiveness and system-wide impact of using Hepatitis C-viremic donors for heart transplant.

Authors:  Brian Wayda; Alexander T Sandhu; Justin Parizo; Jeffrey J Teuteberg; Kiran K Khush
Journal:  J Heart Lung Transplant       Date:  2021-09-13       Impact factor: 10.247

2.  Early fibrosis regression by shear wave elastography after successful direct-acting anti-HCV therapy.

Authors:  Mohamed Ahmed Samy Kohla; Ahmed El Fayoumi; Mohamed Akl; Mervat Abdelkareem; Mahmoud Elsakhawy; Sally Waheed; Mai Abozeid
Journal:  Clin Exp Med       Date:  2019-12-02       Impact factor: 3.984

Review 3.  Integrated stress response in hepatitis C promotes Nrf2-related chaperone-mediated autophagy: A novel mechanism for host-microbe survival and HCC development in liver cirrhosis.

Authors:  Srikanta Dash; Yucel Aydin; Tong Wu
Journal:  Semin Cell Dev Biol       Date:  2019-08-08       Impact factor: 7.727

4.  Extracellular Vesicle Release Promotes Viral Replication during Persistent HCV Infection.

Authors:  Yucel Aydin; Ali Riza Koksal; Venu Reddy; Dong Lin; Hanadi Osman; Zahra Heidari; Sadeq Mutlab Rhadhi; William C Wimley; Mansour A Parsi; Srikanta Dash
Journal:  Cells       Date:  2021-04-22       Impact factor: 6.600

5.  Burden of Liver Cirrhosis in Portugal between 2010 and 2017.

Authors:  João Manuel Silva; Mário Jorge Silva; Filipe Calinas; Paulo Jorge Nogueira
Journal:  GE Port J Gastroenterol       Date:  2020-10-19

6.  The risk of hepatitis C virus recurrence in hepatitis C virus-infected patients treated with direct-acting antivirals after achieving a sustained virological response: A comprehensive analysis.

Authors:  Peng Huang; Yan Wang; Ming Yue; Zhijun Ge; Xueshan Xia; Andre J Jeyarajan; Jacinta A Holmes; Rongbin Yu; Chuanwu Zhu; Sheng Yang; Wenyu Lin; Raymond T Chung
Journal:  Liver Int       Date:  2021-06-16       Impact factor: 8.754

Review 7.  Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment.

Authors:  Srikanta Dash; Yucel Aydin; Kyle E Widmer; Leela Nayak
Journal:  J Hepatocell Carcinoma       Date:  2020-04-15

8.  Bilateral lung transplantation in cystic fibrosis with hepatitis C infection - a study of two cases.

Authors:  Nikola Ruszel; Bartosz Kubisa; Piotr Lisowski; Maria Piotrowska; Michał J Kubisa; Mirosław Brykczyński; Małgorzata Wojtyś; Jarosław Pieróg; Michalina Czarnecka; Janusz Wójcik; Norbert Wójcik; Piotr Sielicki; Michał Bielewicz; Tomasz Grodzki
Journal:  Kardiochir Torakochirurgia Pol       Date:  2019-10-28

9.  Effectiveness of generic direct-acting agents for the treatment of hepatitis C: systematic review and meta-analysis.

Authors:  Hugo Perazzo; Rodolfo Castro; Paula M Luz; Mariana Banholi; Rafaela V Goldenzon; Sandra W Cardoso; Beatriz Grinsztejn; Valdilea G Veloso
Journal:  Bull World Health Organ       Date:  2019-11-08       Impact factor: 9.408

Review 10.  An evaluation of ledipasvir + sofosbuvir for the treatment of chronic hepatitis C infection.

Authors:  Pearson Balatow; Amber Sandlin; Theodore James Cory
Journal:  Expert Opin Pharmacother       Date:  2021-07-01       Impact factor: 4.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.